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Gastric cancer remains one of the most common 
malignancies in Japan despite its reduced incidence 
and mortality. At the time of diagnosis, approxi-
mately 50% of patients with gastric cancer have 
metastatic disease. A number of randomized clinical 
trials have established the role of chemotherapy in 
the treatment of these patients. Previous reports 
demonstrated that patients who received chemother-
apy had longer survival, when comparing chemother-
apy plus best supportive care with best supportive 
care alone4,5,23,25). However, a standard combination 
chemotherapy regimen for advanced gastric cancer 
has not been well established. Recent reports have 
demonstrated that a response rate of 25.0 - 42.9% 
has been reported for S-1 applied to liver metastatic 
foci, and when combined with CDDP its response 
rate has been reported to be increased to up to 
54.0%17). Therefore, the standard therapy for ad-
vanced gastric cancer with distant metastasis and 
recurrence is the systemic chemotherapy of S-1 com-
bined with CDDP3,11). Herein, we report a case of 
metachronous liver metastases of gastric cancer, in 
which a pathological complete response of gastric 
liver metastases was confirmed after 3 cycles of 
chemotherapy with S-1 and CDDP.
CASE REPORTS
A 58-year-old woman visited her family doctor 
due to epigastric pain. She received gastroendo-
scopic examination and was diagnosed as type 2 
advanced gastric cancer located in the upper part. 
She was transferred to our surgical division on 
March 1, 2011. There was nothing particular in her 
family history. She was 151 cm tall and 35.8 kg in 
weight on admission. No abnormal findings were 
found on laboratory findings other than a slight 
elevation of CEA level (CEA: 7.65 ng/ml). Upper 
gastrointestinal endoscopy showed a type 2 tumor 
in the upper part of the stomach (Fig. 1-a, b) and 
endoscopic biopsy revealed signet-ring cell carcino-
ma and tub1. Abdominal computed tomography (CT) 
showed thickening of the gastric wall and peri-
gastric lymphadenopathy (Fig. 1-c). Under the pre-
operative diagnosis of advanced gastric cancer (U, 
post, type2, 45 × 30 mm, cT4a (SE), cN1, cH0, cP0, 
cM0, cStageIIIA), the patient underwent total 
gastrectomy with Roux en Y reconstruction and 
cholecystectomy in March 11, 2011. The resected 
surgical specimen showed a type 3 gastric cancer 
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A 58-year-old woman with advanced gastric cancer underwent total gastrectomy in May 2012. 
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Fig. 1. (a) (b) Endoscopy showed a type 2 tumor in the 
upper part of the stomach. (c) CT showed gastric wall 
thickening and perigastric lymphadenopathy.
Fig. 2. (a) Gross finding of the surgical specimens 
showed a type 3 gastric cancer. (b) Microscopic findings 
revealed the main part was poorly differentiated 
adenocarcinoma.
Fig. 3. (a) (b) Abdominal CT  before combined S-1/
CDDP therapy showed two nodules (S8, S7/8). (c) (d) 
Both nodules were remarkably diminished after 3 
cycles of S-1/CDDP chemotherapy.
Fig. 4. (a) (b) The surgical specimens revealed no 
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DISCUSSION
Clinical trials of S-1 plus CDDP for advanced 
gastric cancer have yielded good responses and the 
treatment was well tolerated. In this S-1 plus 
CDDP versus S-1 alone in RCT in the treatment for 
advanced gastric cancer, it has been verified that 
overall survival is better in patients with advanced 
gastric cancer with S-1 plus CDDP than with S-1 
alone3,13). Therefore, S-1 plus CDDP holds promise of 
becoming a standard first-line treatment for patients 
with advanced gastric cancer. In fact, there have 
been reports that combined use of S-1 and CDDP 
achieved complete response for gastric cancer with 
multiple liver metastases2,6,7,18). Including our case, 
the referral to surgical oncology is a crucial step 
for the documentation of pathological complete re-
sponse. Anyway, it has been established that the 
strategy of combined use of S-1 and CDDP provides 
a promising treatment for far advanced gastric 
cancer with a limited number of liver metastases.
Early tumor detection, standardized surgical 
treatment including lymph node dissection and ap-
propriate adjuvant therapy have improved the sur-
vival of patients with primary gastric cancer in 
Japan22). However, distant metastases of gastric 
cancer to the liver jeopardize the likelihood of a 
cure of the disease and the liver is considered a 
major site of treatment failure. Liver resection has 
been widely accepted as an effective treatment for 
metastatic colorectal cancer, and the indications 
for this procedure have been expanded to include 
all technically resectable metastases numbering 
four or more12,15,28). However, the benefits of a sur-
gical approach to metastatic gastric cancer have 
remained debatable. This is because of extrahepatic 
diseases and advanced cancer progression such as 
peritoneal dissemination or extensive lymph node 
metastases14,29). Therefore, the indications of surgi-
cal resection of liver metastases in advanced gastric 
cancer are generally accepted as follows: (1) Perito-
neal metastases or intensive periaortic lymphade-
nopathy are not found. (2) Liver ?metastasis lesions 
are resectable and curability B has to be achieved9). 
It has been reported that the recurrence rate after 
hepatectomy of gastric cancer metastases is 54.0%, 
which is considered to be high, and that the resec-
tion rate after hepatic recurrence is only 23.0%8). 
A previous report documented that the rate of 
liver metastases from gastric cancer was 4-14%, 
while the rate of hepatic resection remained at only 
1-21%18). Out of patients who underwent liver resec-
tion for the treatment of metastases arising from 
gastric cancer, a few have survived long-term. These 
reports indicate that the 5-year survival and MST 
(mean survival time) after hepatectomy for metas-
tases from gastric cancer range from 11.0 to 42.0% 
and from 12.0 to 21.4 months, respectively1,20,21,27). 
Recent reports revealed that all patients who sur-
(Fig. 2-a) and the histological findings of gastric 
cancer revealed poorly differentiated (por1) > moder-
ated differentiated adenocarcinoma (tub2) > signet 
ring cell carcinoma (sig) (Fig. 2-b). The final diagno-
sis was as follows: Gastric cancer U post type3 5.5 × 
3.8 cm por1 > tub2 > sig se sci INFc ly1 v0 pPM0 
pDM0 n (+) 2/61 pT4a pN1 cM0 f-StageIIIA. The 
CEA value had become normal (3.34 ng/ml) on 
April 12, 2011. Peroral administration of S-1 was 
started in conformity with the guideline two 
months after surgery. However, abdominal CT im-
ages showed two nodules (S8, S7/8) on the liver six 
months after the operation (Fig. 3-a, b) and the 
CEA levels were also increased to 14.58 ng/ml on 
September 11. Therefore, we diagnosed two nodules 
as metachronous metastatic lesions from gastric 
cancer and the chemotherapy was switched to S-1 
(80 mg/body) plus CDDP (70 mg/body) in November 
2012. TS-1 (80 mg/body) was administrated from 
day 1 to 21 followed by 14 days rest as one course. 
CDDP (70 mg/body) was infused on day 1. After 3 
courses of this combination chemotherapy, remark-
able diminution of the metastatic lesions was 
observed (Fig. 3-c, d), and FDG-PET revealed no 
accumulation. However, because of the adverse 
event of Grade 2 nausea, chemotherapy was discon-
tinued. Because the general condition of the patient 
was stable, she underwent S8, S7/8 partial hepatec-
tomy for liver metastasis to enhance the curability 
on March 26, 2012. The resected specimens showed 
no apparent evidence of metastatic tumor, although 
uneven fatty deposition was observed more fre-
quently than in the surrounding tissue (Fig. 4-a, b), 
and designated as histologically complete response 
(CR). The patient has been alive 30 months after 
the second operation without any visible recurrent 
sites, although the tumor marker had been main-
tained at relatively high levels (Fig. 5).
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A case in whichi metachronous multiple hepatic me-
tastasis occurred after operation for Stomach cancer 
and CR was achieved by S-1 monotherapy. Carcinoma 
vived for more than 5 years after initial hepatecto-
my had a solitary metastasis, and no patient with 
multiple metastatic disease survived beyond 3 
years10,16,24). These reports indicated that the num-
ber of liver metastases, solitary or multiple, is a 
significant predictive factor and patients with a 
solitary liver metastasis are good candidates for 
surgical resection, whereas the number of liver me-
tastases arising from colorectal cancer is no longer 
considered an important predictor of long term 
survival15,25).
We herein reported a case of metachronous liver 
metastases of gastric cancer, in which a pathologi-
cally complete response of gastric liver metastases 
was confirmed histologically after 3 cycles of com-
bined chemotherapy with S-1 and CDDP. The pa-
tient survived till September 2014, 30 months after 
hepatic resections of liver metastases. The patient 
had not received any chemotherapy, because she 
herself refused to undergo chemotherapy due to a 
severe adverse event. However, a favorable progno-
sis has been observed and no recurrences has been 
detected up to now by CT/MRI and PET images, 
although the tumor marker has not returned to 
under the normal level (CEA < 5 ng/ml). A previous 
report showed that the absence of serosal invasion 
was another influential factor for a good prognosis 
after hepatectomy, because the dissemination of 
malignant cells to the abdominal cavity is as fatal 
and controllable as extensive lymph node metasta-
ses and scattered liver lesions13). Thus, serosal in-
vasion of primary gastric cancer is a significant 
poor prognostic factor following resection of gastric 
liver metastases. In conclusion, strict observation 
is needed for the development of peritoneal recur-
rences, because our case was positive in serosal in-
vasion of primary gastric cancer.
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